Cargando…
Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved in several processes including the angiogenic pathway. They are very stable in biological fluids, which turn...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796251/ https://www.ncbi.nlm.nih.gov/pubmed/29361687 http://dx.doi.org/10.3390/ijms19010307 |
_version_ | 1783297468674342912 |
---|---|
author | Ulivi, Paola Canale, Matteo Passardi, Alessandro Marisi, Giorgia Valgiusti, Martina Frassineti, Giovanni Luca Calistri, Daniele Amadori, Dino Scarpi, Emanuela |
author_facet | Ulivi, Paola Canale, Matteo Passardi, Alessandro Marisi, Giorgia Valgiusti, Martina Frassineti, Giovanni Luca Calistri, Daniele Amadori, Dino Scarpi, Emanuela |
author_sort | Ulivi, Paola |
collection | PubMed |
description | Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved in several processes including the angiogenic pathway. They are very stable in biological fluids, which turns them into potential circulating biomarkers. In this study, we considered a case series of patients with metastatic (m) CRC treated with a bevacizumab (B)-based treatment, enrolled in the prospective multicentric Italian Trial in Advanced Colorectal Cancer (ITACa). We then analyzed a panel of circulating miRNAs in relation to the patient outcome. In multivariate analysis, circulating basal levels of hsa-miR-20b-5p, hsa-miR-29b-3p and hsa-miR-155-5p resulted in being significantly associated with progression-free survival (PFS) (p = 0.027, p = 0.034 and p = 0.039, respectively) and overall survival (OS) (p = 0.044, p = 0.024 and p = 0.032, respectively). We also observed that an increase in hsa-miR-155-5p at the first clinical evaluation was significantly associated with shorter PFS (HR 3.03 (95% CI 1.06–9.09), p = 0.040) and OS (HR 3.45 (95% CI 1.18–10.00), p = 0.024), with PFS and OS of 9.5 (95% CI 6.8–18.7) and 15.9 (95% CI 8.4–not reached), respectively, in patients with an increase ≥30% of hsa-miR-155-5p and 22.3 (95% CI 10.2–25.5) and 42.9 (24.8–not reached) months, respectively, in patients without such increase. In conclusion, our results highlight the potential usefulness of circulating basal levels of hsa-miR-20b-5p, hsa-miR-29b-3p and hsa-miR-155-5p in predicting the outcome of patients with mCRC treated with B. In addition, the variation of circulating hsa-miR-155-5p could also be indicative of the patient survival. |
format | Online Article Text |
id | pubmed-5796251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57962512018-02-09 Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer Ulivi, Paola Canale, Matteo Passardi, Alessandro Marisi, Giorgia Valgiusti, Martina Frassineti, Giovanni Luca Calistri, Daniele Amadori, Dino Scarpi, Emanuela Int J Mol Sci Article Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved in several processes including the angiogenic pathway. They are very stable in biological fluids, which turns them into potential circulating biomarkers. In this study, we considered a case series of patients with metastatic (m) CRC treated with a bevacizumab (B)-based treatment, enrolled in the prospective multicentric Italian Trial in Advanced Colorectal Cancer (ITACa). We then analyzed a panel of circulating miRNAs in relation to the patient outcome. In multivariate analysis, circulating basal levels of hsa-miR-20b-5p, hsa-miR-29b-3p and hsa-miR-155-5p resulted in being significantly associated with progression-free survival (PFS) (p = 0.027, p = 0.034 and p = 0.039, respectively) and overall survival (OS) (p = 0.044, p = 0.024 and p = 0.032, respectively). We also observed that an increase in hsa-miR-155-5p at the first clinical evaluation was significantly associated with shorter PFS (HR 3.03 (95% CI 1.06–9.09), p = 0.040) and OS (HR 3.45 (95% CI 1.18–10.00), p = 0.024), with PFS and OS of 9.5 (95% CI 6.8–18.7) and 15.9 (95% CI 8.4–not reached), respectively, in patients with an increase ≥30% of hsa-miR-155-5p and 22.3 (95% CI 10.2–25.5) and 42.9 (24.8–not reached) months, respectively, in patients without such increase. In conclusion, our results highlight the potential usefulness of circulating basal levels of hsa-miR-20b-5p, hsa-miR-29b-3p and hsa-miR-155-5p in predicting the outcome of patients with mCRC treated with B. In addition, the variation of circulating hsa-miR-155-5p could also be indicative of the patient survival. MDPI 2018-01-20 /pmc/articles/PMC5796251/ /pubmed/29361687 http://dx.doi.org/10.3390/ijms19010307 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ulivi, Paola Canale, Matteo Passardi, Alessandro Marisi, Giorgia Valgiusti, Martina Frassineti, Giovanni Luca Calistri, Daniele Amadori, Dino Scarpi, Emanuela Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer |
title | Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer |
title_full | Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer |
title_fullStr | Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer |
title_full_unstemmed | Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer |
title_short | Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer |
title_sort | circulating plasma levels of mir-20b, mir-29b and mir-155 as predictors of bevacizumab efficacy in patients with metastatic colorectal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796251/ https://www.ncbi.nlm.nih.gov/pubmed/29361687 http://dx.doi.org/10.3390/ijms19010307 |
work_keys_str_mv | AT ulivipaola circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer AT canalematteo circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer AT passardialessandro circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer AT marisigiorgia circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer AT valgiustimartina circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer AT frassinetigiovanniluca circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer AT calistridaniele circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer AT amadoridino circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer AT scarpiemanuela circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer |